Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin Containing Chemotherapy

Clinical Cancer Research, 02/28/2013

The purpose of this study was to evaluate clinical implications of CD33 single–nucleotide polymorphisms (SNP) in pediatric patients with acute myeloid leukemia (AML) treated with gemtuzumab–ozogamicin (GO)–based therapy. This data suggest that genetic variations in CD33 could impact clinical outcome of GO–based therapy in pediatric AMLs.

Print Article Summary Cat 2 CME Report